Sheba Medical Center, one of Israel’s largest hospital systems, has signed on to deploy OpenAI’s enterprise healthcare platform, ChatGPT for Healthcare, making it the first hospital outside the United States to gain access to the product, according to trade coverage of the deal reported in late July and August. The partnership extends OpenAI’s healthcare push beyond its home market for the first time since the company began courting hospital systems in earnest at the start of 2026.
From Consumer Chatbot to Hospital Infrastructure
OpenAI formally introduced OpenAI for Healthcare in January 2026 as a dedicated set of products aimed at both healthcare organizations and consumers, following years in which hospitals and individual clinicians had already been using general-purpose ChatGPT informally — and often against official IT policy — for tasks like drafting patient communications or summarizing medical literature. The enterprise push represented an attempt to formalize that usage with better data governance, audit trails and integration options suited to a regulated industry, rather than leaving adoption to ad hoc clinician workarounds.
What OpenAI Can Point to So Far
Boston Children’s Hospital, one of OpenAI’s earliest enterprise healthcare partners, reported this year that its deployment helped reclaim roughly 60,000 work hours and save more than $7 million through AI-enabled administrative and clinical workflows — figures OpenAI has used to court additional hospital systems, including internationally. The company has also moved to expand access beyond enterprise deals: on July 23, OpenAI broadened its consumer-facing Health feature to all eligible U.S. users 18 and older, and separately launched ChatGPT for Clinicians, offered at no cost to verified U.S.-based physicians, nurse practitioners, physician assistants and pharmacists.
The Case for Going Global Early
Sheba Medical Center has cultivated a reputation as an early adopter of digital health technology within Israel’s tightly integrated, data-rich national health system, making it a logical first international proving ground for OpenAI: a sophisticated academic medical center with existing digital infrastructure and a patient population covered by Israel’s universal health insurance system, reducing some of the reimbursement and data-fragmentation complexity that can slow AI adoption in the more fragmented U.S. hospital market. For OpenAI, landing a flagship international hospital partner also serves a strategic purpose beyond Israel itself — demonstrating to other health systems worldwide that its enterprise healthcare platform can operate under a different country’s data protection and clinical governance requirements.
The Case for Caution
John Brownstein, Boston Children’s Hospital’s chief innovation officer and a vocal advocate for AI adoption in medicine, has nonetheless warned publicly that a serious AI-related adverse event in a clinical setting is a real risk the industry needs to prepare for, saying “I think it’s very likely we’ll see it.” That warning carries particular weight as OpenAI’s healthcare tools expand into new regulatory environments like Israel’s, where data protection rules, clinical liability standards and health system structures differ meaningfully from the U.S., raising questions about whether safeguards built for one country’s hospitals translate cleanly to another’s.
What’s Next
Sheba’s deployment will be watched closely as a test case for whether OpenAI’s hospital-focused products can operate effectively outside the U.S. regulatory and reimbursement environment they were originally built around, with other health systems in Europe, the Gulf and Asia likely to watch the rollout before committing to similar partnerships of their own. The real measure of success won’t be the signing of the deal itself, but whether Sheba can replicate — or improve on — the kind of time and cost savings OpenAI has touted from its U.S. hospital partners, under a genuinely different healthcare system’s rules.
Photo: Tima Miroshnichenko / PEXELS via Pexels
